睿知中国疾病研究地图
候选清单0

正在招募B 细胞急性淋巴细胞白血病早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06793241,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. 3. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;

    入选标准第 3 条

  3. 4. Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation;

    排除标准第 4 条

    9. Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening;

    排除标准第 9 条

  4. 10. ECOG score 0-2;

    入选标准第 14 条

  5. 6. Total bilirubin ≤51 ( μmol/L), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L);

    入选标准第 10 条

    7. Absolute neutrophil count: ≥ 0.5×109/L; Platelet: ≥ 30×109/L; Hemoglobin ≧60g/L;

    入选标准第 11 条

  6. 5. Hiv-infected person;

    排除标准第 5 条

    6. Persons with active hepatitis B or C virus; Those who are not cured have active infections;

    排除标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06793241,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. Age ≥18 years old, gender unlimited;
  2. 2. Abnormal B cell immunotyping was CD19 positive;
  3. 3. Patients diagnosed with B-cell acute lymphoblastic leukemia by histological or immunotyping;
  4. 4. Meets the diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and includes any of the following conditions:
  5. No CR was obtained after standard chemotherapy;
  6. CR was induced for the first time, but the duration of CR was less than 12 months;
  7. R/R B-ALL that does not work after the first or more remedial treatments;
  8. Two or more relapses;
  9. 5. The researchers believed that the patient had been adequately treated, such as auto-HSCT, auto-CART could not be prepared or preparation failed. Autologous CAR-T preparation failure was defined as including too few autologous lymphocytes (<1×109) or insufficient expansion during preparation or failure to meet the release criteria;
  10. 6. Total bilirubin ≤51 ( μmol/L), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L);
  11. 7. Absolute neutrophil count: ≥ 0.5×109/L; Platelet: ≥ 30×109/L; Hemoglobin ≧60g/L;
  12. 8. Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%;
  13. 9. The estimated survival is more than 3 months;
  14. 10. ECOG score 0-2;
  15. 11. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);
  16. 12. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.

排除标准:Exclusion Criteria:

  1. 1. Known allergies to research preconditioning measures, etc;
  2. 2. People with a history of epilepsy or other central nervous system disorders;
  3. 3. People with a history of prolonged QT or severe heart disease;
  4. 4. Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation;
  5. 5. Hiv-infected person;
  6. 6. Persons with active hepatitis B or C virus; Those who are not cured have active infections;
  7. 7. Insufficient amplification ability (< 5x) in response to CD3 / CD28 costimulatory signals;
  8. 8. Combined use of systemic steroids (e.g., prednisone ≥20mg) within 3 days prior to screening, except for ongoing or intermittent use of topical, inhaled or intranasal steroids within 2 weeks or at present; Or have systemic diseases that require long-term use of immunological agents;
  9. 9. Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening;
  10. 10. Any situation that the investigator believes may increase the risk of the subjects or interfere with the study results.

引自 ClinicalTrials.gov, NCT06793241, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06793241,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06793241